Fate Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune disorders. Its proprietary platform uses clonal master iPSC lines to manufacture CAR T-cell and natural killer (NK) cell product candidates that are designed to be uniform, scalable, and available without patient-specific manufacturing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key pipeline programs include FT819, an iPSC-derived CD19-targeted CAR T-cell therapy in development for systemic lupus erythematosus and lupus nephritis; FT522, a CAR NK candidate for B-cell lymphoma and autoimmunity; and FT825, a solid-tumor program partnered with Ono Pharmaceutical. Because the company has not yet commercialized a product, investors follow FATE primarily for clinical data readouts, regulatory milestones, and its ability to sustain a cash runway through development.
Over the last 30 days, FATE has fallen approximately 53%, declining from a closing price of about $2.07 in late October to roughly $0.97 in recent trading. The move was uneven: shares held near the $2.00–$2.10 range through late October before breaking lower after the early-November earnings release and subsequent financing disclosures, with sharp single-day declines through mid-November.
The broader trend is even steeper. Over the trailing quarter, the stock has declined roughly 60%, sliding from about $2.45 in mid-August to below $1.00. The multi-month decline reflects sustained pressure from limited revenue, ongoing operating losses, and recurring equity-financing concerns rather than a single isolated catalyst.
Several verified developments drove the recent sell-off. On November 5, 2026, Fate Therapeutics reported third-quarter results showing collaboration revenue of $0, down from $1.7 million in the prior-year period, after Ono Pharmaceutical's research and nonclinical development obligations concluded in June. The company posted a net loss of $30.7 million for the quarter and reported cash, cash equivalents, and short-term investments of $139.1 million. From what I see, this revenue drop marked a clear turning point in sentiment.
On the same day, the company disclosed a new at-the-market sales agreement with Leerink Partners allowing it to sell up to $100 million of common stock, while terminating its prior Jefferies ATM program. A related S-3 registration statement subsequently became effective on November 12, 2026, reinforcing the prospect of additional share issuance and weighing on sentiment.
Analyst actions were mixed. BofA raised its price target to $2.50 while maintaining a Neutral rating, Wedbush and Piper Sandler reiterated Buy ratings, and Wells Fargo and Cantor Fitzgerald maintained Hold ratings. The combination of zero revenue, persistent losses, and dilution risk overshadowed these views and drove the shares lower.
The quarterly decline reflects a larger narrative of transition and funding pressure. Although the company made clinical progress—including the initiation of the RECLAIM-LN Phase 2 trial of FT819 in lupus nephritis and a $15 million CIRM grant—the end of Ono-funded activities removed a meaningful revenue source, leaving the company fully reliant on its balance sheet to fund development.
With no approved products and significant expected operating losses, investors have increasingly focused on dilution risk and cash runway rather than clinical milestones. This shift in emphasis, combined with broad weakness in pre-revenue biotech names, has driven FATE progressively lower over the quarter even as the underlying pipeline advanced.
Looking ahead, investors are likely to monitor several factors. Clinical data from the RECLAIM-LN Phase 2 trial of FT819 in lupus nephritis and initial dosing in the COMPLETE study of FT839 remain important catalysts. Updates on the $15 million CIRM grant and any regulatory alignment with the FDA on registrational pathways will also matter.
Financially, the pace of ATM share sales, the company's cash position, and its ability to extend its runway toward its stated mid-2028 target will shape sentiment. Broader macroeconomic conditions, biotech-sector risk appetite, and any analyst rating or price-target revisions may also influence trading. These factors represent key areas of focus rather than predictions of future performance. I’m watching this closely as the situation develops.
In my own work, I have found Tickeron’s AI Trading Bots helpful for observing how automated strategies respond to volatile names like FATE. The platform offers a range of bots with different timeframes and approaches, which can provide additional context when evaluating pre-revenue biotechs amid financing events and clinical updates. This perspective has become a regular part of how I cross-check market positioning.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where FATE declined for three days, in 305 of 338 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 45 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
The Aroon Indicator for FATE entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.596). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. FATE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical stage biopharmaceutical company
Industry Biotechnology